Sensible Immune has introduced that the primary grownup leukemia affected person has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells utilizing ProTcell at Memorial SloanKettering Most cancers Heart (MSK).
The phaseI/II trial is a multicenter, open-label, first-in-human research anticipated to enroll as much as 36 grownup and pediatric sufferers with hematological malignancies, and has been designed to evaluate the security and the potential of SMART101 to enhance scientific outcomes of hematopoietic stem cell transplantation (HSCT).
The primary enrolled affected person acquired a SMART101 injection in December 2022; no associated hostile occasions have been reported.
Frédéric Lehmann, chief medical officer of Sensible Immune, stated: “The infusion of the primary affected person is a major milestone in our journey to handle the problem of sluggish immune reconstitution after allogeneic HSCT, utilizing the ability of the thymus. We’re grateful to the devoted investigators at MSK and look ahead to persevering with enrollment on this necessary trial.”
Karine Rossignol, chief government officer and co-founder of SmartImmune, stated: “We’re excited to sponsor this pioneering trial. Accelerated reconstitution of a full polyclonal T-cell repertoire after stem cell transplantation may enhance each high quality of life and scientific outcomes for sufferers with acute leukemia, and we look ahead to releasing extra information because the trial progresses.”
About Sensible Immune’s SMART101
SMART101 is generated ex vivo in seven days from allogeneic bloodstem cells, utilizing Sensible Immune’s ProTcell T-cell remedy platform. As soon as injected into the affected person, the SMART101 human T-cell progenitors journey to the thymus the place they’re educated to grow to be totally practical and self-tolerant T-cells.
Preclinical information recommend that the ProTcell platform may reconstitute the immune system in 100 days as an alternative of the 12 to 18 months noticed in physiology, thereby defending sufferers from an infection and relapse. SMART101 is produced by Sensible Immune’s contract growth and manufacturing group associate in France, the MEARY Heart for Cell and Gene Remedy at Paris St Louis Hospital (Help Publique – Hôpitaux de Paris, AP-HP).
